Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression

References

• Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87–108. doi:10.3322/caac.21262
   PubMed Web of Science ®Google Scholar
• Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R, Jemal A. Cancer treatment and survivorship statistics, 2016. CA: a cancer journal for clinicians. 2016;66(4):271–89. doi:10.3322/caac.21349
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: a cancer journal for clinicians. 2016;66(1):7–30. doi:10.3322/caac.21332
   PubMed Web of Science ®Google Scholar
• Wu X, Liu D, Tao D, Xiang W, Xiao X, Wang M, Wang L, Luo G, Li Y, Zeng F, et al. BRD4 Regulates EZH2 Transcription through Upregulation of C-MYC and Represents a Novel Therapeutic Target in Bladder Cancer. Mol Cancer Ther. 2016;15(5):1029–42. doi:10.1158/1535-7163.MCT-15-0750
   PubMed Web of Science ®Google Scholar
• Yang Z, Yik JH, Chen R, He N, Jang MK, Ozato K, Zhou Q. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol Cell. 2005;19(4):535–45. doi:10.1016/j.molcel.2005.06.029
   PubMed Web of Science ®Google Scholar
• Jang MK, Mochizuki K, Zhou M, Jeong HS, Brady JN, Ozato K. The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol Cell. 2005;19(4):523–34. doi:10.1016/j.molcel.2005.06.027
   PubMed Web of Science ®Google Scholar
• Shi J, Vakoc CR. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol Cell. 2014;54(5):728–36. doi:10.1016/j.molcel.2014.05.016
   PubMed Web of Science ®Google Scholar
• Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, Rodig SJ, Kung AL, Bradner JE, Weinstock DM. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120(14):2843–52. doi:10.1182/blood-2012-02-413021
   PubMed Web of Science ®Google Scholar
• Lockwood WW, Zejnullahu K, Bradner JE, Varmus H. Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins. Proc Natl Acad Sci U S A. 2012;109(47):19408–13. doi:10.1073/pnas.1216363109
   PubMed Web of Science ®Google Scholar
• Sanchez R, Meslamani J, Zhou MM. The bromodomain: from epigenome reader to druggable target. Biochim Biophys Acta. 2014;1839(8):676–85. doi:10.1016/j.bbagrm.2014.03.011
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–73. doi:10.1038/nature09504
   PubMed Web of Science ®Google Scholar
• Sonenberg N, Hinnebusch AG. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell. 2009;136(4):731–45. doi:10.1016/j.cell.2009.01.042
   PubMed Web of Science ®Google Scholar
• Wang J, Ye Q, She QB. New insights into 4E-BP1-regulated translation in cancer progression and metastasis. Cancer Cell Microenviron. 2014;1(5):e331. doi:10.14800/ccm.331.
   Google Scholar
• Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75(2):250–63. doi:10.1158/0008-5472.CAN-14-2789
   PubMed Web of Science ®Google Scholar
• Robichaud N, del Rincon SV, Huor B, Alain T, Petruccelli LA, Hearnden J, Goncalves C, Grotegut S, Spruck CH, Furic L, et al. Phosphorylation of eIF4E promotes EMT and metastasis via translational control of SNAIL and MMP-3. Oncogene. 2015;34(16):2032–42. doi:10.1038/onc.2014.146
   PubMed Web of Science ®Google Scholar
• Jones RM, Branda J, Johnston KA, Polymenis M, Gadd M, Rustgi A, Callanan L, Schmidt EV. An essential E box in the promoter of the gene encoding the mRNA cap-binding protein (eukaryotic initiation factor 4E) is a target for activation by c-myc. Mol Cell Biol. 1996;16(9):4754–64. doi:10.1128/MCB.16.9.4754
   PubMed Web of Science ®Google Scholar
• Zhang B, Dong S, Zhu R, Hu C, Hou J, Li Y, Zhao Q, Shao X, Bu Q, Li H, et al. Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3. Oncotarget. 2015;6(26):22799–811. doi:10.18632/oncotarget.4332
   PubMedGoogle Scholar
• Seal J, Lamotte Y, Donche F, Bouillot A, Mirguet O, Gellibert F, Nicodeme E, Krysa G, Kirilovsky J, Beinke S, et al. Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg Med Chem Lett. 2012;22(8):2968–72. doi:10.1016/j.bmcl.2012.02.041
   PubMed Web of Science ®Google Scholar
• Ma Z, Zhu L, Luo X, Zhai S, Li P, Wang X. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3beta in NSCLC cells. Cancer Biol Ther. 2012;13(11):1009–17. doi:10.4161/cbt.20989
   PubMed Web of Science ®Google Scholar
• Chen X, Zhu L, Ma Z, Sun G, Luo X, Li M, Zhai S, Li P, Wang X. Oncogenic miR-9 is a target of erlotinib in NSCLCs. Sci Rep. 2015;5:17031. doi:10.1038/srep17031
   PubMed Web of Science ®Google Scholar
• Mathis JM, Williams BJ, Sibley DA, Carroll JL, Li J, Odaka Y, Barlow S, Nathan CO, Li BD, DeBenedetti A. Cancer-specific targeting of an adenovirus-delivered herpes simplex virus thymidine kinase suicide gene using translational control. J Gene Med. 2006;8(9):1105–20. doi:10.1002/jgm.935
   PubMed Web of Science ®Google Scholar
• Liang S, Guo R, Zhang Z, Liu D, Xu H, Xu Z, Wang X, Yang L. Upregulation of the eIF4E signaling pathway contributes to the progression of gastric cancer, and targeting eIF4E by perifosine inhibits cell growth. Oncol Rep. 2013;29(6):2422–30. doi:10.3892/or.2013.2397
   PubMed Web of Science ®Google Scholar
• Huang W, Yang L, Liang S, Liu D, Chen X, Ma Z, Zhai S, Li P, Wang X. AEG-1 is a target of perifosine and is over-expressed in gastric dysplasia and cancers. Dig Dis Sci. 2013;58(10):2873–80. doi:10.1007/s10620-013-2735-5
   PubMed Web of Science ®Google Scholar
• Svitkin YV, Herdy B, Costa-Mattioli M, Gingras AC, Raught B, Sonenberg N. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol Cell Biol. 2005;25(23):10556–65. doi doi:10.1128/MCB.25.23.10556-10565.2005
   PubMed Web of Science ®Google Scholar
• Li Y, Yue P, Deng X, Ueda T, Fukunaga R, Khuri FR, Sun SY. Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia. 2010;12(10):848–55. doi:10.1593/neo.10704
   PubMed Web of Science ®Google Scholar
• Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY. Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012;13(5):272–80. doi:10.4161/cbt.18923
   PubMed Web of Science ®Google Scholar
• Lynch M, Chen L, Ravitz MJ, Mehtani S, Korenblat K, Pazin MJ, Schmidt EV. hnRNP K binds a core polypyrimidine element in the eukaryotic translation initiation factor 4E (eIF4E) promoter, and its regulation of eIF4E contributes to neoplastic transformation. Mol Cell Biol. 2005;25(15):6436–53. doi:10.1128/MCB.25.15.6436-6453.2005
   PubMed Web of Science ®Google Scholar
• Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, Kastritis E, Gilpatrick T, Paranal RM, Qi J, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–17. doi:10.1016/j.cell.2011.08.017
   PubMed Web of Science ®Google Scholar
• Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Dis. 2013;3(3):308–23. doi:10.1158/2159-8290.CD-12-0418
   Web of Science ®Google Scholar
• Sengupta S, Biarnes MC, Clarke R, Jordan VC. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement. Breast Cancer Res Treat. 2015;150(2):265–78. doi:10.1007/s10549-015-3319-1
   PubMed Web of Science ®Google Scholar
• Baratta MG, Schinzel AC, Zwang Y, Bandopadhayay P, Bowman-Colin C, Kutt J, Curtis J, Piao H, Wong LC, Kung AL, et al. An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. Proc Natl Acad Sci U S A. 2015;112(1):232–7. doi:10.1073/pnas.1422165112
   PubMed Web of Science ®Google Scholar
• Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478(7370):524–8. doi:10.1038/nature10334
   PubMed Web of Science ®Google Scholar
• Rodriguez RM, Huidobro C, Urdinguio RG, Mangas C, Soldevilla B, Dominguez G, Bonilla F, Fernandez AF, Fraga MF. Aberrant epigenetic regulation of bromodomain BRD4 in human colon cancer. J Mol Med. 2012;90(5):587–95. doi:10.1007/s00109-011-0837-0
   PubMed Web of Science ®Google Scholar
• Lenhart R, Kirov S, Desilva H, Cao J, Lei M, Johnston K, Peterson R, Schweizer L, Purandare A, Ross-Macdonald P, et al. Sensitivity of Small Cell Lung Cancer to BET Inhibition Is Mediated by Regulation of ASCL1 Gene Expression. Mol Cancer Ther. 2015;14(10):2167–74. doi:10.1158/1535-7163.MCT-15-0037
   PubMed Web of Science ®Google Scholar
• Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, Robson SC, Chung CW, Hopf C, Savitski MM, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478(7370):529–33. doi:10.1038/nature10509
   PubMed Web of Science ®Google Scholar
• Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA, Bergeron L, Sims RJ, 3rd. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A. 2011;108(40):16669–74. doi:10.1073/pnas.1108190108
   PubMed Web of Science ®Google Scholar
• Moerke NJ, Aktas H, Chen H, Cantel S, Reibarkh MY, Fahmy A, Gross JD, Degterev A, Yuan J, Chorev M, et al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell. 2007;128(2):257–67. doi:10.1016/j.cell.2006.11.046
   PubMed Web of Science ®Google Scholar
• Hong DS, Kurzrock R, Oh Y, Wheler J, Naing A, Brail L, Callies S, Andre V, Kadam SK, Nasir A, et al. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2011;17(20):6582–91. doi:10.1158/1078-0432.CCR-11-0430
   PubMed Web of Science ®Google Scholar
• Jacobson BA, Thumma SC, Jay-Dixon J, Patel MR, Dubear Kroening K, Kratzke MG, Etchison RG, Konicek BW, Graff JR, Kratzke RA. Targeting eukaryotic translation in mesothelioma cells with an eIF4E-specific antisense oligonucleotide. PloS One. 2013;8(11):e81669. doi 10.1371/journal.pone.0081669. doi:10.1371/journal.pone.0081669
   PubMed Web of Science ®Google Scholar
• Thumma SC, Jacobson BA, Patel MR, Konicek BW, Franklin MJ, Jay-Dixon J, Sadiq A, De A, Graff JR, Kratzke RA. Antisense oligonucleotide targeting eukaryotic translation initiation factor 4E reduces growth and enhances chemosensitivity of non-small-cell lung cancer cells. Cancer Gene Ther. 2015;22(8):396–401. doi:10.1038/cgt.2015.34
   PubMed Web of Science ®Google Scholar
• Lu C, Makala L, Wu D, Cai Y. Targeting translation: eIF4E as an emerging anticancer drug target. Expert Rev Mol Med. 2016;18:e2. doi:10.1017/erm.2015.20
   PubMed Web of Science ®Google Scholar
• Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI, Young RA. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell. 2013;153(2):320–34. doi:10.1016/j.cell.2013.03.036
   PubMed Web of Science ®Google Scholar
• Huang B, Yang XD, Zhou MM, Ozato K, Chen LF. Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol Cell Biol. 2009;29(5):1375–87. doi:10.1128/MCB.01365-08
   PubMed Web of Science ®Google Scholar